Collectively, our work demonstrates for the first time that the signals downstream of IRE1 may impact NSCLC progression, and points toward an alternative therapeutic avenue coupled with personalized molecular diagnosis for decreasing tumor cells’ adaptive properties, and modulating the tumor aggressiveness through reduced EMT. Here, ERN1 is linked to non-small cell lung carcinoma.